Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01966445 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
A Phase 1 study of Cancer and Neoplasms, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 14
- Study locations
NCT01966445 is a Phase 1 study of Cancer and Neoplasms that has completed, run by GlaxoSmithKline. The registered enrollment target is 29 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 14 study locations across 6 states.
The verdict
NCT01966445, a Phase 1 study of Cancer and Neoplasms, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 14
- Study locations
Study Summary
Human Epidermal Growth Factor Receptor 3 (HER3) expression is seen across a wide variety of solid malignancies and is associated with poor prognosis. Up-regulation of HER3 expression and activity is also associated with resistance to multiple pathway inhibitors. GSK2849330, a monoclonal antibody targeting HER3, is a new agent for subjects whose tumors express HER3. This study is a phase I, first time in human, open-label, dose escalation study. The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of GSK2849330 in subjects with advanced HER3-positive solid tumors. The study will be conducted in two parts. Part 1 (Dose-Escalation Phase) will include dose escalation and PK/PD cohorts to evaluate safety, PK, and PD to guide selection of dose regimen(s) for Part 2. In Part 2 (Expansion Cohorts), up to 3 cohorts will be enrolled at the dose regimen(s) selected based on Part 1 data, to evaluate safety in a larger cohort of subjects at the recommended dose regimen and also to evaluate preliminary evidence of clinical benefit.
Interventions
- BIOLOGICAL GSK2849330
Study Locations (14)
Other
- GSK Investigational Site - Amsterdam
- GSK Investigational Site - Amsterdam
- GSK Investigational Site - Groningen
- GSK Investigational Site - Groningen
- GSK Investigational Site - Nijmegen
- GSK Investigational Site - Nijmegen
- GSK Investigational Site - Rotterdam
- GSK Investigational Site - Rotterdam
Victoria
- GSK Investigational Site - Heidelberg
- GSK Investigational Site - Melbourne
Colorado
- GSK Investigational Site - Aurora
New York
- GSK Investigational Site - New York
Utah
- GSK Investigational Site - Salt Lake City
Western Australia
- GSK Investigational Site - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-11-26 |
| Est. Completion | 2017-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01966445
The ClinicalTrials.gov registry entry for NCT01966445 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which GSK2849330 is the first listed.
NCT01966445 reports 14 study locations spanning 6 distinct geographic areas - top geographies include Other, Victoria, Colorado.
Frequently Asked Questions
What is clinical trial NCT01966445 about?
NCT01966445 is a clinical study titled "Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors". Human Epidermal Growth Factor Receptor 3 (HER3) expression is seen across a wide variety of solid malignancies and is associated with poor prognosis. Up-regulation of HER3 expression and activity is also associated with resistance to multiple pathway inhibitors. GSK2849330, a monoclonal antibody tar...
What is the current status of trial NCT01966445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2013-11-26. Estimated completion is 2017-09-18.
What conditions does trial NCT01966445 study?
This clinical trial studies the following conditions: Cancer, Neoplasms.
What interventions are being tested in trial NCT01966445?
The interventions under investigation include: GSK2849330 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01966445?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01966445 being conducted?
This trial has 14 study locations across Colorado, New York, Utah, Victoria, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.